Thus, treatments that restore adipose tissue insulin sensitivity and suppress inflammatory responses attenuate the pathology of NAFLD and inhibit its progression to the advanced stages [37,38]; P2Y2R is proposed as a promising therapeutic target. The gene discussed is P2RY2; the disease is metabolic dysfunction-associated steatotic liver disease.